Psychosocial factors and SARS-CoV-2 vaccine hesitancy among moroccan hemodialysis patients
Keywords:
coronavirus disease 19, chronic hemodialysis, vaccination against sars-cov-2, psychosocial barriers, vaccine hesitancyAbstract
Introduction: Patients on dialysis are at increased risk for COVID-19 related complications, and thus a high-priority group for vaccination. However, a substantial fraction of patients on dialysis belong to groups more likely to be hesitant about vaccination.
Objective: Our work aimed to determine hesitancy rates and to describe psychosocial barriers in chronic hemodialysis patients generating a delay in vaccination mainly for the third or booster doses of SARS-CoV-2 vaccine among chronic hemodialysis patients in the Nephrology and Dialysis, Department of the Rabat Military Hospital, Morocco.
Patients and Methods: The trial was designed as a prospective single-center study which included all hemodialysis patients in the nephrology department of the Rabat Military Hospital. Patients were surveyed with an ad hoc questionnaire. The questionnaire explored different domains associated with vaccine hesitancy, such as perception of disease severity, sources of information about the vaccine and the disease, and confidence in the health care system.
Results: We included Forty patients, the mean age of patients were 57 ± 16,7 years were included in this study. The sex ratio (female/male) was 1.2. Mean dialysis duration was 108 months. Personal history of COVID -19 illness was found in 15 patients. 52% of COVID-19 vaccination refusals were more worried about vaccine side effects than COVID-19 infection. Most frequently mentioned sources of information regarding opposition to vaccination were social media (35,8%) followed by self-conviction (22,7%), The odds of vaccine acceptance were higher among women (62%), diabetic patients, students and married patients; and patients who already received an influenzae vaccination
Conclusion: Vaccine hesitancy was not associated with educational level, age, but rather with lack of confidence in vaccine safety and regarding the conspiratorial theory of this pandemic, 50 % of patients believe in it.
References
Shimada N, Shimada H, Itaya Y, Tomino Y. Novel coronavirus disease in patients with end-stage kidney disease. Ther Apher Dial, 2021; 25(5):544-550. doi:10.1111/1744-9987.13599
Meziyerh S, Helm D, Vries APJ. Vulnerabilities in kidney transplant recipients with COVID-19: a single center experience. Transpl Int, 2020; 33(11):1557-1561. doi:10.1111/tri.13714
Liu CK, Ghai S, Waikar SS, Weiner DE. COVID-19 infection risk among hemodialy- sis patients in long-term care facilities. Kid- ney Med, 2020; 2:810–811.
Fisher KA, Bloomstone SJ, Walder J, Craw- ford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: A survey of U.S. adults. Ann Intern Med, 2020; 173:964-973.
Nikoskelainen J, Koskela M, Forsstrom J, Kasanen A, Leinonen M. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int. 1985; 28(4):672-677. doi:10.1038/ki.1985.182
Pitchou Y Kengibe, Jean-Robert R Makulo, Yannick M Nlandu, et al. Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study. Pan Afr Med J, 2019; 34:122. doi:10.11604/pamj.2019.34.122.19603
Carr EJ, Wu M, Harvey R, et al. Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. Lancet. 2022; 399:800-802. https://doi.org/10.1016/S0140- 6736(22)00104-0
Carr EJ, Wu M, Harvey R, et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet. 2021; 398:1038-1041. https://doi.org/10.1016/S0140-6736(21) 01854-7 7. Walls AC, Sprouse KR, Bowen JE, et al. SARS-CoV-2
Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med, 2021; 27:225-228.
Clift K, Rizzolo D. Vaccine myths and mis- conceptions. JAAPA, 2014; 27(8):21–6.
MacDonald NE, Eskola J, Liang X, Chaudhuri, M, Dubé E, Gellinet B, et al. SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine, 2015; 33(34):4161-4.
Lin C, Tu P, Beitsch LM. Confidence and receptivity for COVID-19 vaccines: a rapid systematic review. Vaccines (Basel), 2020; 9:16.
Schwarzinger M, Watson V, Arwidson P, et al. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine character- istics. Lancet Public Health, 2021; 6:e210–e221.
Fisher KA, Bloomstone SJ, Walder J, et al. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. adults. Ann Intern Med. 2020; 173:964–973.
Kerr JR, Freeman ALJ, Marteau TM, et al. Effect of Informa- tion about COVID-19 vaccine effectiveness and side effects on behavioural intentions: two online experiments. Vaccines (Basel), 2021; 9:379.
Battistella C, Quattrin R, Celotto D, et al. Factors predicting influenza vaccination adherence among patients in dialysis: an Italian survey. Hum Vaccin Immunother, 2019; 15:2434–2439.
Wilson RJI, Vergelys C, Ward J, et al. Vaccine hesitancy among general practitioners in Southern France and their reluctant trust in the health authorities. Int J Qual Stud Health Well-being, 2020; 15:1757336.
COCONEL Group. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect Dis, 2020; 20:769–770.
Palamenghi L, Barello S, Boccia S, et al. Mistrust in biomed- ical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. Eur J Epidemiol, 2020; 35:785–788.
Barello S, Nania T, Dellafiore F, et al. ’Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic. Eur J Epidemiol, 2020; 35:781–783.
Colloca L, Barsky AJ. Placebo and nocebo ef- fects. N Engl J Med, 2020; 382(6):554–61.
